Merck Sharp & Dohme MK-8931-017

Drug Development Trials

About the trial

MERCK 017 – A Randomized, Placebo-Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 with a Long Term Double-Blind Extension in Subjects with Mild to Moderate Alzheimer’s Disease.